Clinical Research Directory
Browse clinical research sites, groups, and studies.
Biologics and Sublingual Immunotherapy
Sponsor: Medical University of Silesia
Summary
Most current studies involve using a biological drug to increase the safety of allergen immunotherapy (AIT) especially in the treatment of food allergies, to avoid the risk of anaphylaxis. However, adding Xolair® to AIT may improve the therapy's effectiveness. There are still few observations on this topic, especially in patients with house dust mite (HDM)-driven asthma.
Official title: Adding Biological Therapy to Asthmatic Patients on Allergen Immunotherapy to House Dust Mites
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2024-05-01
Completion Date
2028-03-01
Last Updated
2023-09-07
Healthy Volunteers
No
Conditions
Interventions
omalizumab
adding omalizumab to anti asthmatic therapy